Iswanto Sucandy1, Susannah Cheek2, Benjamin J Golas3, Allan Tsung2, David A Geller2, James W Marsh2. 1. University of Pittsburgh Medical Center/UPMC Liver Cancer Center, Pittsburgh, PA, United States. Electronic address: sucandyi2@upmc.edu. 2. University of Pittsburgh Medical Center/UPMC Liver Cancer Center, Pittsburgh, PA, United States. 3. NewYork-Presbyterian/Weill Cornell Medical Center, New York, NY, United States.
Abstract
BACKGROUND: We aim to investigate long-term survival outcomes in patients undergoing radiofrequency ablation (RFA), based on our longitudinal 5 and 10 year follow-up data. METHODS: All patients who underwent RFA for hepatocellular carcinoma (HCC) and colorectal liver metastasis (CLM) between 1999 and 2010. RESULTS: 320 patients were included with oncologic diagnoses of HCC in 122 (38.1%) and CLM in 198 (61.9%). The majority of patients had a single tumor ablation (71% RFA 1 lesion). Minimum 5 year follow-up information was available in 89% patients, with a median follow-up of 115.3 months. In patients with HCC, disease eventually recurred in 73 (64%) patients. In patients with CLM, disease recurrence was ultimately seen in 143 (84.1%) patients. In the HCC group, the 5- and 10-year overall survivals were 38.5% and 23.4%, while in the CLM group, the 5- and 10-year overall survivals were 27.6% and 15%, respectively. CONCLUSIONS: The use of RFA as a part of treatment strategy for primary and metastatic liver tumors imparts 10-year overall survivals of >23% and 15%, respectively. This study indicates that long-term survival is possible with RFA treatment.
BACKGROUND: We aim to investigate long-term survival outcomes in patients undergoing radiofrequency ablation (RFA), based on our longitudinal 5 and 10 year follow-up data. METHODS: All patients who underwent RFA for hepatocellular carcinoma (HCC) and colorectal liver metastasis (CLM) between 1999 and 2010. RESULTS: 320 patients were included with oncologic diagnoses of HCC in 122 (38.1%) and CLM in 198 (61.9%). The majority of patients had a single tumor ablation (71% RFA 1 lesion). Minimum 5 year follow-up information was available in 89% patients, with a median follow-up of 115.3 months. In patients with HCC, disease eventually recurred in 73 (64%) patients. In patients with CLM, disease recurrence was ultimately seen in 143 (84.1%) patients. In the HCC group, the 5- and 10-year overall survivals were 38.5% and 23.4%, while in the CLM group, the 5- and 10-year overall survivals were 27.6% and 15%, respectively. CONCLUSIONS: The use of RFA as a part of treatment strategy for primary and metastatic liver tumors imparts 10-year overall survivals of >23% and 15%, respectively. This study indicates that long-term survival is possible with RFA treatment.
Authors: S Arii; Y Yamaoka; S Futagawa; K Inoue; K Kobayashi; M Kojiro; M Makuuchi; Y Nakamura; K Okita; R Yamada Journal: Hepatology Date: 2000-12 Impact factor: 17.425
Authors: Francesco Ardito; Maria Vellone; Alessandra Cassano; Agostino M De Rose; Carmelo Pozzo; Alessandro Coppola; Bruno Federico; Ivo Giovannini; Carlo Barone; Gennaro Nuzzo; Felice Giuliante Journal: J Gastrointest Surg Date: 2012-12-08 Impact factor: 3.452
Authors: Waleed Shady; Elena N Petre; Mithat Gonen; Joseph P Erinjeri; Karen T Brown; Anne M Covey; William Alago; Jeremy C Durack; Majid Maybody; Lynn A Brody; Robert H Siegelbaum; Michael I D'Angelica; William R Jarnagin; Stephen B Solomon; Nancy E Kemeny; Constantinos T Sofocleous Journal: Radiology Date: 2015-08-12 Impact factor: 11.105
Authors: Xinyang Liu; William Plishker; Timothy D Kane; David A Geller; Lung W Lau; Jun Tashiro; Karun Sharma; Raj Shekhar Journal: Int J Comput Assist Radiol Surg Date: 2020-04-22 Impact factor: 2.924
Authors: K J Paprottka; F Schoeppe; M Ingrisch; J Rübenthaler; N N Sommer; E De Toni; H Ilhan; M Zacherl; A Todica; P M Paprottka Journal: Eur J Nucl Med Mol Imaging Date: 2017-02-14 Impact factor: 9.236
Authors: Yik-Kiong Hue; Alexander R Guimaraes; Ouri Cohen; Erez Nevo; Abraham Roth; Jerome L Ackerman Journal: IEEE Trans Med Imaging Date: 2017-09-18 Impact factor: 10.048
Authors: Hakm Y Murad; Emma P Bortz; Heng Yu; Daishen Luo; Gray M Halliburton; Andrew B Sholl; Damir B Khismatullin Journal: Sci Rep Date: 2019-12-20 Impact factor: 4.379